PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a d ...

公司产品进展 - 公司正在开发一种名为Lenivia的新型抗体疗法，用于治疗犬类骨关节炎疼痛 [1] - 该疗法若获批，单次注射即可为犬类提供长达三个月的OA疼痛缓解效果 [1]